AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 191 min read$SGRY

DeLuca Teresa purchased $144K of SGRY

DeLuca Teresa purchased 10,000 shares of Surgery Partners, Inc. (SGRY) at $14.35 ($0.14M total) on 2026-08-18.

Original reporting
SEC EDGAR · DeLuca Teresa
Published Aug 19, 2026, 8:17 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 19, 2026, 8:24 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$SGRY
Bullish
medium confidence
Mentioned
$SGRY
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SGRYBullishLow
01

Why it matters

The director's purchase adds a modest bullish signal but is unlikely to move the stock significantly.

02

Market read

Insider buying is a positive indicator but the modest size limits market impact.

03

What to watch

The transaction size is small relative to overall float; no immediate catalyst beyond the filing.

Relevance 5/10Novelty 5/10Timing: transaction dated 2026-08-18, reported on 2026-08-19

Background

Form 4 filings disclose insider transactions and are primary sources of new information.

Company-level read

Ticker impact

$SGRYBullishMedium confidence
Context

Director Teresa DeLuca purchased 10,000 shares of Surgery Partners for $143,500, increasing her stake to 66,843 shares.

Expected impact

Modest upside pressure as the market digests the insider purchase.

Evidence & confidence

The purchase size is modest relative to the company's market cap, but insider buying is generally viewed favorably.

Market effects

Sector

Minimal impact on the healthcare services sector.

Regional

Limited to U.S. markets where the stock trades.

Global

Low

Counterpoint

What could challenge this read

The purchase may be routine portfolio rebalancing rather than a strong endorsement.

Key entities

  • Company
    Surgery Partners, Inc.

    Provider of outpatient surgery facilities.

  • Insider
    Teresa DeLuca

    Director of Surgery Partners.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

SGRY insider trading history →

Related articles

AUG 17
$SGRYMedAI 8/10

Surgery Partners (SGRY) Q2 2026 Earnings Call Transcript

Surgery Partners (SGRY) reported Q2 2026 net revenue of about $849 million, up 2.7% year over year, and adjusted EBITDA of about $125 million, with a 14.7% margin. Same-facility net revenue rose 5%. For the first half, net revenue was about $1.66 billion (+3.6%) and adjusted EBITDA about $228 million. The company reaffirmed full-year guidance and said it will update forward guidance after a pending Idaho Falls transaction closes.

yahoo.com8 min
AUG 11
$SGRYMed

Surgery Partners: Q2 Earnings Snapshot

Surgery Partners Inc. (SGRY) reported a Q2 loss of $15 million, or 12 cents per share. Adjusted earnings were 10 cents per share, and revenue was $848.9 million. The company expects full-year revenue of $3.35 billion to $3.45 billion, according to its earnings release.

local3news.com2 min
AUG 10
$SGRYMed

Surgery Partners Q2 Earnings Call Highlights

Surgery Partners (NASDAQ:SGRY) reported Q2 same-facility revenue up 4.9% for the first half, driven by a 0.8% case increase and 4% net revenue per case. Management said commercial payer mix fell to about 49% of Q2 net revenue, with government payments rising. The company signed agreements to sell Idaho Falls assets for about $795M gross consideration and reaffirmed 2026 guidance excluding the deal.

finance.yahoo.com6 min
AUG 10
$SGRYMed

Surgery Partners shares edge lower despite Q2 revenue beat

Surgery Partners (NASDAQ:SGRY) shares fell 0.71% pre-market after Q2 results were mixed. Revenue rose to $848.9M, above the $830.05M forecast, and same-facility revenue grew 5%. Adjusted EPS was $0.10 vs $0.06 consensus, but GAAP net loss was $0.12/share. Adjusted EBITDA fell to $125.2M. Company reaffirmed 2026 revenue $3.35B-$3.45B and adjusted EBITDA at least $530M.

finance.yahoo.com4 min
AUG 10
$SGRYMedAI 8/10

Surgery Partners Q2 2026 slides show 5% revenue growth, Idaho exit

Surgery Partners (NASDAQ:SGRY) reported Q2 2026 revenue of $848.9M, above an $830.05M estimate, but posted an adjusted loss of $0.12 per share versus a $0.06 profit expectation. Same-facility revenue grew 5.0% on 4.8% rate growth. The company reaffirmed 2026 guidance: $3.35B to $3.45B revenue and at least $530M adjusted EBITDA, excluding the pending Idaho Falls divestiture.

investing.com6 min